Itolizumab, new drug for COVID-19 patients to cost Rs 8,000 per vial

Biotechnology major Biocon on Monday said it will launch biologic drug Itolizumab for the treatment of moderate to severe COVID-19 patients at a price of around 8,000 per vial.   The company......

'No preparedness planning, no accountability, no action plan'

'This government did not have any plan for safety stocks of essential medicines.' IMAGE: Doctors attend to a patient suffering from COVID-19 inside the emergency room at the Safdarjung Hospital in......

'Ready To Launch 5 products In 18 Months'

'We recently launched Yesintek in the immunology space.' Photograph: Kind courtesy Biocon Biologics Ltd Biocon Biologics Ltd (BBL) reported robust growth in 2024-25 (FY25), driven by rising......

Jt drugs controller waives trial of Biocon drug; arrested

The CBI has arrested Joint Drugs Controller S Eswara Reddy for allegedly receiving a Rs 4 lakh bribe to waive the phase three clinical trial of the Insulin Aspart injection, a product of Biocon......

'Tariffs will hurt insurance, patients and everyone'

'If people have to build new facilities, and by the time they are operational, it will be time for a new President in the US.' Photograph: Amit Dave/Reuters After registering a net profit of Rs......

Rupee Slide: Tough Times For Overseas Corporate Debt

Raising overseas debt has become prohibitively expensive due to the depreciating rupee. Photograph: Kind courtesy Jatinder Jeetu/Pixabay Indian companies' foreign borrowings plunged 20.2 per cent......